Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
about
Exposure to polycyclic aromatic hydrocarbons and serum inflammatory markers of cardiovascular diseaseMarkers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patientsGenetic loci on chromosome 5 are associated with circulating levels of interleukin-5 and eosinophil count in a European population with high risk for cardiovascular disease.Elevated hemostasis markers after pneumonia increases one-year risk of all-cause and cardiovascular deathsThe challenges for molecular nutrition research 2: quantification of the nutritional phenotype.Diabetic dyslipidemia and exercise alter the plasma low-density lipoproteome in Yucatan pigs.Saturated Fat Consumption and Risk of Coronary Heart Disease and Ischemic Stroke: A Science Update.Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantationAutonomic function and prothrombotic activity in women after an acute coronary event.Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the Cardiovascular Health Study.Randomised clinical trial of an intensive intervention in the primary care setting of patients with high plasma fibrinogen in the primary prevention of cardiovascular disease.Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies.Hemostasis, inflammation, and fatal and nonfatal coronary heart disease: long-term follow-up of the atherosclerosis risk in communities (ARIC) cohort.Is thrombin a key player in the 'coagulation-atherogenesis' maze?Association of antiretroviral therapy with fibrinogen levels in HIV-infection.Association between Fibrinogen and Carotid Atherosclerosis According to Smoking Status in a Korean Male Population.The risk and burden of smoking related heart disease mortality among young people in the United States.Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease.Effect of Soymilk Consumption on Waist Circumference and Cardiovascular Risks among Overweight and Obese Female Adults.Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT studyA Japanese cross-sectional multicentre study of biomarkers associated with cardiovascular disease in smokers and non-smokersCardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.Heterogeneity of systemic inflammatory responses to periodontal therapy.Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT studyFactor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele.Platelet glycoproteins and fibrinogen in recovery from idiopathic sudden hearing loss.Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis.Fibrinogen as a key regulator of inflammation in disease.Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present).Onion: nature protection against physiological threats.Fibrin binds to collagen and provides a bridge for αVβ3 integrin-dependent contraction of collagen gelsBlood viscosity as a forgotten factor and its effect on pulmonary flow.Evaluation of circulating endothelial biomarkers in familial Mediterranean fever.C-reactive protein variations for different chronic somatic disorders.Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.Fibrinogen facilitates atherosclerotic formation in Sprague-Dawley rats: A rodent model of atherosclerosis.Levels of plasma fibrinogen are elevated in well-controlled rheumatoid arthritis.Prenatal arachidonic acid exposure and selected immune-related variables in childhood.Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression.
P2860
Q23915092-7050BDC6-918A-454C-A53E-F55D6AE5430CQ27024262-DBD61390-D1AD-4266-8467-CED6EDF2DDAFQ27315831-7F8F1AD9-7D16-4318-8747-6EF100330BC8Q28741566-B06B6C2C-E940-4924-9974-49ED20F3ED7CQ30493853-008D3ABE-2670-4E2D-A746-2A3D9E53A415Q33809676-CD989E75-745D-4B39-87E8-E690B29A42E5Q33810706-8B2781BD-BD66-42A6-80A0-66B9B49F5039Q33887123-CE9903AC-9ACB-498D-AA6E-72E78AC36CE0Q34150160-740734DE-341C-4F9A-971D-82796C9845FFQ34153553-8C7C0E1E-FA05-48FD-A8EC-7FC6E11EDD33Q34158475-B91DF42A-F893-496E-B302-3877D17B1998Q34180573-1CE30D6C-ED2A-4B96-A07C-0FE4BFA1C849Q34593955-B42368F5-B150-41EB-A486-51ECB6AC52C2Q34674022-5287A590-6BFF-465B-9777-14242F30BC11Q34948467-B90F1874-F1A0-4D6E-96C9-2A6089AD618DQ35166181-148E74FC-4A26-42F2-B2EF-323125A98705Q35778283-15C84AE6-8A49-4317-A3A0-89B835E76168Q35814892-7C6E1F97-4D69-48B4-8D0C-4B53118C5A13Q35968147-AF7A0B2F-99AD-4DD9-A9EA-9B8EBE33D6B7Q36422654-681417B7-A965-4B3A-BE1B-2A96E42A9F89Q36429404-6D34ED77-2218-463C-B3D1-7DF8A125D0E1Q36482388-07AB81AA-AF0F-4D9C-B08F-DFA6987D5BB3Q36679594-C2F78764-9823-4C5F-AB66-3377168C9959Q37365945-61C428B5-56CD-4B1D-B147-7F678970F5CFQ37393182-0A62608C-B7EC-4552-B38F-F1B2E9DF2C6DQ37457665-E518238E-0EA7-4002-AE3B-857E51376461Q37510585-137B38A7-CEF9-4AC1-B069-40D3DCFC7EE0Q37850385-B1D962D5-C021-42BD-932A-6D4638A24AD8Q37950860-377A2415-41F3-4F0B-B873-4A0F3E7406E1Q38092174-9626F873-D9CD-4D7E-9D23-2CA59C2DD924Q38219182-14B21AFE-9EB5-4118-B57A-68DEB4EDB1E7Q38993771-6F3AB08E-DA07-4CDD-9D62-661185A193D8Q39730317-4335FB85-DF1A-4AF6-86AD-D43D256C5CC5Q40259279-03F5FD8C-2B4F-4FE1-98A6-1CB46B83F27FQ40392144-71DE5546-CEAA-430F-BEE2-823157F12AA4Q42164828-EDB8D213-0CB0-40E8-8C5A-4E2AE9EBB2A3Q43245970-518AD92C-0B5E-4639-917D-7EAA2D40599FQ43509736-65EB91F6-4B68-439C-B216-B0176F5C20E3Q46144142-17C9C651-DCD5-4EC9-8420-A48A6526826FQ47652085-870B487F-F613-4D76-B915-45A6AFDE5804
P2860
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
@ast
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
@en
type
label
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
@ast
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
@en
prefLabel
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
@ast
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
@en
P1433
P1476
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
@en
P2093
William B Kannel
P2888
P304
P356
10.1007/S11745-005-1488-8
P577
2005-12-01T00:00:00Z